Key facts
- FastWave Medical’s last known valuation is $30.0M (May 2022).
- It has raised $40.0M; the latest was Early Stage VC ($19.0M) in Dec 2024.
- Notable investors include Epic Venture Partners, Grand Pharmaceutical Group, M&L Group, SCP Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for FastWave Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for FastWave Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FastWave Medical
Developer of intravascular devices designed for the arterial to be safe, efficacious, and cost-effective. The company offers novel, secure, and cost-effective IVL catheters engineered for crossing complex lesions and tortuous anatomy, with reliable usability and a streamlined profile, angioplasty balloons provide smooth performance, enabling medical professionals to treat patients in a mannered way.
- Sector
- Healthcare
- HQ
- Minneapolis, MN, United States
- Founded
- 2021
- Employees
- 27
- Website
- fastwavemedical.com/
- Ownership
- Privately Held (backing)
FastWave Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FastWave Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FastWave Medical in its N-PORT filings yet. We sweep new filings monthly.